SINOMED(688108)2025-02-26 07:50Financial Performance - Total revenue for 2024 reached RMB 458.74 million, a year-on-year increase of 33.64%[3] - Net profit attributable to shareholders was RMB 1.52 million, representing a significant increase of 103.84% compared to the previous year[5] - The basic earnings per share improved to RMB 0.004, a 104.00% increase from the previous year[8] - The weighted average return on equity increased to 0.18%, up 4.93 percentage points from the previous year[3] - The company experienced a significant reduction in losses, with operating profit improving by 75.58% year-on-year[8] - Non-recurring losses decreased, contributing to a 64.79% increase in net profit attributable to shareholders after excluding non-recurring items[12] Assets and Equity - The company's total assets at the end of the reporting period were RMB 1,300.56 million, up 9.68% from the end of the previous year[6] - The net asset value per share rose to RMB 2.10, reflecting a 5.00% increase from the previous year[6] Revenue Growth - Revenue from coronary intervention business grew by 59% due to the implementation of the national centralized procurement policy[7] Research and Development - Research and development expenses totaled RMB 201.92 million, an increase of 21.57% year-on-year, accounting for 44.02% of total revenue[11]